$392 Million is the total value of Kynam Capital Management, LP's 34 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $70,290,000 | +51.5% | 2,200,000 | +64.3% | 17.95% | +19.3% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $48,335,000 | +43.9% | 2,512,240 | +30.0% | 12.34% | +13.3% |
| NTRA | Buy | NATERA INC | $43,912,000 | +11.7% | 1,239,047 | +28.2% | 11.21% | -12.1% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $30,526,000 | +19.0% | 1,132,259 | +50.4% | 7.80% | -6.3% |
| TVTX | Buy | TRAVERE THERAPEUTICS INC | $29,928,000 | +33.3% | 1,235,151 | +41.8% | 7.64% | +5.0% |
| VERA | Buy | VERA THERAPEUTICS INCcl a | $20,724,000 | +75.6% | 1,522,712 | +203.1% | 5.29% | +38.2% |
| GOSS | Buy | GOSSAMER BIO INC | $19,673,000 | +23.7% | 2,350,448 | +28.3% | 5.02% | -2.6% |
| BIIB | Buy | BIOGEN INC | $16,101,000 | +99.9% | 78,951 | +106.5% | 4.11% | +57.4% |
| PCVX | Buy | VAXCYTE INC | $15,749,000 | +12.5% | 723,781 | +24.9% | 4.02% | -11.4% |
| BNR | Buy | BURNING ROCK BIOTECH LTDsponsored ads | $12,513,000 | +74.2% | 4,300,000 | +456.2% | 3.20% | +37.2% |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $9,909,000 | – | 936,563 | +100.0% | 2.53% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $9,666,000 | +78.0% | 900,000 | +56.9% | 2.47% | +40.1% |
| COGT | New | COGENT BIOSCIENCES INC | $9,020,000 | – | 1,000,000 | +100.0% | 2.30% | – |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $6,828,000 | -37.4% | 590,143 | +0.1% | 1.74% | -50.7% |
| LQDA | Buy | LIQUIDIA CORPORATION | $6,543,000 | -21.4% | 1,500,718 | +29.4% | 1.67% | -38.1% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $5,975,000 | -20.8% | 4,009,893 | +74.8% | 1.53% | -37.7% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $5,514,000 | +44.2% | 1,696,735 | -11.2% | 1.41% | +13.5% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $5,324,000 | -64.0% | 175,000 | -63.8% | 1.36% | -71.6% |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $4,210,000 | – | 1,000,000 | +100.0% | 1.08% | – |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $3,691,000 | -38.5% | 757,848 | +13.3% | 0.94% | -51.6% |
| CLDX | New | CELLDEX THERAPEUTICS INC NEWcall | $2,476,000 | – | 246,400 | +100.0% | 0.63% | – |
| MRUS | Sell | MERUS N V | $2,346,000 | -24.0% | 103,627 | -11.3% | 0.60% | -40.2% |
| FATE | Sell | FATE THERAPEUTICS INC | $2,009,000 | -43.3% | 81,064 | -11.2% | 0.51% | -55.4% |
| AFMD | Buy | AFFIMED N V | $1,942,000 | +27.7% | 701,029 | +101.5% | 0.50% | +0.6% |
| AKUS | Sell | AKOUOS INC | $1,800,000 | -2.3% | 383,784 | -1.1% | 0.46% | -23.1% |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $1,653,000 | -12.2% | 579,915 | -11.3% | 0.42% | -30.8% |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $1,014,000 | -15.2% | 249,229 | -11.3% | 0.26% | -33.2% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCput | $925,000 | – | 50,000 | +100.0% | 0.24% | – |
| MCRB | Sell | SERES THERAPEUTICS INC | $887,000 | -57.3% | 258,647 | -11.3% | 0.23% | -66.3% |
| CNTB | Buy | CONNECT BIOPHARMA HLDGS LTDads | $643,000 | -6.5% | 739,649 | +224.8% | 0.16% | -26.5% |
| CABA | Sell | CABALETTA BIO INC | $580,000 | -53.6% | 546,800 | -11.3% | 0.15% | -63.5% |
| KRTX | New | KARUNA THERAPEUTICS INCput | $578,000 | – | 38,900 | +100.0% | 0.15% | – |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $166,000 | +137.1% | 93,434 | -11.9% | 0.04% | +82.6% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $128,000 | -51.5% | 124,701 | -11.2% | 0.03% | -61.6% |
| NKTR | Exit | NEKTAR THERAPEUTICSput | $0 | – | -200,000 | -100.0% | -0.08% | – |
| TGTX | Exit | TG THERAPEUTICS INCput | $0 | – | -258,600 | -100.0% | -0.13% | – |
| KRYS | Exit | KRYSTAL BIOTECH INC | $0 | – | -18,393 | -100.0% | -0.40% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -185,514 | -100.0% | -0.53% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -193,280 | -100.0% | -2.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.